Get the Stockscreener App
11.55
17.50%
1.72
Pre-market:
11.89
0.34
+2.94%
Immunitybio Inc stock is traded at $11.55, with a volume of 82.63M.
It is up +17.50% in the last 24 hours and up +79.07% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$9.83
Open:
$10.15
24h Volume:
82.63M
Relative Volume:
2.73
Market Cap:
$11.38B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-11.91
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+91.86%
1M Performance:
+79.07%
6M Performance:
+400.00%
1Y Performance:
+258.70%
1-Day Range:
$9.95
$12.28
1-Week Range:
$6.06
$12.28
52-Week Range:
$1.83
$12.28
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
11.55 | 9.68B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.43 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.19 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.28 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.85 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
369.00 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook - Meyka
ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump - Insider Monkey
ImmunityBio, Inc. (IBRX): Harnessing a 407% Revenue Growth with a Promising 28% Upside Potential - DirectorsTalk Interviews
Selecky of Immunitybio sells $250,000 in shares - Investing.com
Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million - Investing.com
IBRX Stock Rallies Into Trump’s Big SOTU Night — Here’s What Traders Think Could Fuel The Next Move - Stocktwits
Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million By Investing.com - Investing.com Nigeria
Selecky of Immunitybio sells $250,000 in shares By Investing.com - Investing.com Nigeria
ImmunityBio higher after early-stage trial results for cell therapy in lymphoma - MSN
ImmunityBio's Anktiva Drives Record Revenue Amid Global Expansion Push - AD HOC NEWS
ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity - Yahoo Finance
ImmunityBio (IBRX) Stock Explodes 500%+ in 2026 on ANKTIVA's 700% Revenue Surge - International Business Times Australia
ImmunityBio Expands Reach: ANKTIVA Gains Conditional EU Approval - StocksToTrade
European Nod Boosts ImmunityBio’s Market Presence - timothysykes.com
ImmunityBio reports $113M in ANKTIVA sales, up 700% in 2025 - Investing.com India
Goldman Sachs, H.C. Wainwright Maintain Buy on ImmunityBio, Inc. (IBRX) Feb 2026 - Meyka
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight - GuruFocus
IBRX Stock Surges Past 4-Year Highs: Analyst Sees over 50% Upside After Anktiva’s Blowout Growth - Stocktwits
Why ImmunityBio (IBRX) Is Up 65.3% After ANKTIVA’s European Approval And New Regional Partnerships - simplywall.st
IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans, hints at cancer breakthrough - MSN
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit - Investing News Network
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundatio - PharmiWeb.com
ImmunityBio, Inc. SEC 10-K Report - TradingView
Stock Market Today, Feb. 23: ImmunityBio Surges After Anktiva Revenue Jumps 700% - Yahoo Finance
IMMUNITYBIO ($IBRX) Releases Q4 2025 Earnings - Quiver Quantitative
H.C. Wainwright raises Immunitybio stock price target to $15 By Investing.com - Investing.com India
H.C. Wainwright raises Immunitybio stock price target to $15 - Investing.com India
Why ImmunityBio stock is soaring again today - MSN
ImmunityBio Shares Rise After Q4 Results - marketscreener.com
Why ImmunityBio Stock Is Soaring Again Today - Yahoo Finance
ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth - Bitget
ImmunityBio Shares Surge On 700% Revenue Growth Driven By AnktivaImmunityBio (NASDAQ:IBRX) - Benzinga
ImmunityBio Expands EU Market Presence with ANKTIVA Approval - StocksToTrade
ImmunityBio, Inc. (IBRX) Stock: Surges 15% as ANKTIVA Revenue Jumps 700% in 2025 - CoinCentral
ImmunityBio Authorized to Roll Out ANKTIVA in Europe and Saudi Arabia - timothysykes.com
ImmunityBio Posts 700% Revenue Growth, Expanded Anktiva Approvals; Stock Up - Nasdaq
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally - BioSpace
ImmunityBio: Q4 Earnings Snapshot - kens5.com
ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
ImmunityBio: Fourth Quarter Financial Highlights - Bitget
ImmunityBio Surges as EU Greenlights Key Cancer Therapy - StocksToTrade
Immunitybio Inc earnings beat by $0.05, revenue topped estimates By Investing.com - Investing.com Canada
Immunitybio Inc earnings beat by $0.05, revenue topped estimates - Investing.com Canada
ImmunityBio Expands Bladder Cancer Drug Reach Across Europe - timothysykes.com
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market - Asianet Newsable
ImmunityBio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
ImmunityBio Stock Sinks Despite Bold Global Expansion - TipRanks
ImmunityBio (IBRX) stock rises premarket after ANKTIVA sales surge, cash burn still in view - TechStock²
ImmunityBio reports $113M in ANKTIVA sales, up 700% in 2025 By Investing.com - Investing.com Canada
ImmunityBio surges as ANKTIVA revenue jumps 700% in breakthrough 2025 - grafa.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):